Acorda Therapeutics, Inc.
ACORDelisted Apr 25, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001008848
Acorda Therapeutics, Inc. was delisted on Apr 25, 2024; its insiders filed their last Form 4 on Jun 23, 2023; 17 institutions reported holding it in 13F filings for Q1 2024, worth $2.13M in total; no superinvestor held it.
Q2 2024 vs. Q1 2024
How the institutions holding Acorda Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 17 | 2 | −15 |
| Shares | 166.4K | 33.7K | −132.7K (−79.8%) |
| Value | $2.13M | $8.00K | −$2.13M (−99.6%) |
New holders (0)
Institutions that held Acorda Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
None.
Sold out (15)
Institutions that held Acorda Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Davidson Kempner Capital Management LP | 55,145 | $689.3K |
| Renaissance Technologies LLC | 46,761 | $618.0K |
| Vanguard Group Inc | 19,260 | $254.4K |
| BlackRock Inc. | 6,107 | $80.7K |
| Wells Fargo & Company | 3,736 | $49.4K |
| Morgan Stanley | 1,137 | $15.0K |
| Russell Investments Group, Ltd. | 300 | $3.75K |
| UBS Group AG | 106 | $1.40K |
| Tower Research Capital LLC (TRC) | 103 | $1.36K |
| Bank of America Corp | 51 | $674 |
| FMR LLC | 9 | $114 |
| JPMorgan Chase & Co | 4 | $50 |
| First Manhattan Co | 3 | $39 |
| Qube Research & Technologies Ltd | 1 | $13 |
| Royal Bank of Canada | 14 | $0 |